IDEAS home Printed from https://ideas.repec.org/a/gam/jsusta/v11y2019i5p1289-d210054.html
   My bibliography  Save this article

From Rare to Neglected Diseases: A Sustainable and Inclusive Healthcare Perspective for Reframing the Orphan Drugs Issue

Author

Listed:
  • Marialuisa Saviano

    (Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy)

  • Sergio Barile

    (Department of Management, “Sapienza” University of Rome, Via del Castro Laurenziano 9, 00161 Roma, Italy)

  • Francesco Caputo

    (Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy)

  • Mattia Lettieri

    (Unipegaso, 80132 Naples, Italy)

  • Stefania Zanda

    (Department of Management, “Sapienza” University of Rome, Via del Castro Laurenziano 9, 00161 Roma, Italy)

Abstract

This work is about how healthcare issues can be reframed from a sustainable and inclusive development perspective. Focusing on the case of orphan drugs and rare diseases, first, a country-based review of the main regulatory approaches to orphan drugs is conducted; then, the main contributions of the literature are reviewed to identify dominant views and the way the problem is more commonly framed. The main findings reveal that the dominant regulatory approaches and theoretical interpretations of the problem are mainly based on economic considerations. However, this does not seem to have led to very satisfactory results. Reflecting upon what the sustainability perspective can highlight with reference to healthcare, substantial connections between the orphan drugs issue and that of neglected diseases are highlighted. These connections suggest reframing the orphan drugs issue as a social equality and inclusiveness problem, hence the need to adopt a sustainable and inclusive development perspective. As a key sustainable development goal (SGD) to be shared by all nations, healthcare should always be approached by putting the principles of sustainable and inclusive development at the core of policy makers’ regulatory choices. Accordingly, we think that the orphan drugs issue, like that of neglected diseases, could be better faced by adopting a social equality and inclusiveness perspective.

Suggested Citation

  • Marialuisa Saviano & Sergio Barile & Francesco Caputo & Mattia Lettieri & Stefania Zanda, 2019. "From Rare to Neglected Diseases: A Sustainable and Inclusive Healthcare Perspective for Reframing the Orphan Drugs Issue," Sustainability, MDPI, vol. 11(5), pages 1-21, March.
  • Handle: RePEc:gam:jsusta:v:11:y:2019:i:5:p:1289-:d:210054
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/2071-1050/11/5/1289/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/2071-1050/11/5/1289/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Marianna Cavazza & Yllka Kodra & Patrizio Armeni & Marta Santis & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arr, 2016. "Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 19-29, April.
    2. Aris Angelis & Panos Kanavos & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & Va, 2016. "Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 31-42, April.
    3. Richard Mallett & Jessica Hagen-Zanker & Rachel Slater & Maren Duvendack, 2012. "The benefits and challenges of using systematic reviews in international development research," Journal of Development Effectiveness, Taylor & Francis Journals, vol. 4(3), pages 445-455, September.
    4. Alain Denis & Lut Mergaert & Christel Fostier & Irina Cleemput & Steven Simoens, 2010. "Issues surrounding orphan disease and orphan drug policies in Europe," Applied Health Economics and Health Policy, Springer, vol. 8(5), pages 343-350, September.
    5. Francesco Polese & Luca Carrubbo & Francesco Caputo & Debora Sarno, 2018. "Managing Healthcare Service Ecosystems: Abstracting a Sustainability-Based View from Hospitalization at Home (HaH) Practices," Sustainability, MDPI, vol. 10(11), pages 1-15, October.
    6. Leisinger, Klaus M., 2005. "The Corporate Social Responsibility of the Pharmaceutical Industry: Idealism without Illusion and Realism without Resignation," Business Ethics Quarterly, Cambridge University Press, vol. 15(4), pages 577-594, October.
    7. Georgi Iskrov & Itziar Astigarraga & Rumen Stefanov & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Arrigo Schieppati & Domenica Tarusc, 2016. "Social/economic costs and health-related quality of life in patients with histiocytosis in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 67-78, April.
    8. Karine Chevreul & Coralie Gandré & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schiep, 2016. "Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 43-52, April.
    9. F. M. Scherer, 1993. "Pricing, Profits, and Technological Progress in the Pharmaceutical Industry," Journal of Economic Perspectives, American Economic Association, vol. 7(3), pages 97-115, Summer.
    10. Callahan, D. & Jennings, B., 2002. "Ethics and public health: Forging a strong relationship," American Journal of Public Health, American Public Health Association, vol. 92(2), pages 169-176.
    11. Francesco Caputo & Luca Carrubbo & Debora Sarno, 2018. "The Influence of Cognitive Dimensions on the Consumer-SME Relationship: A Sustainability-Oriented View," Sustainability, MDPI, vol. 10(9), pages 1-19, September.
    12. Wellman-Labadie, Olivier & Zhou, Youwen, 2010. "The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?," Health Policy, Elsevier, vol. 95(2-3), pages 216-228, May.
    13. Petra Maresova & Blanka Klimova & Kamil Kuca, 2016. "Financial and legislative aspects of drug development of orphan diseases on the European market -- a systematic review," Applied Economics, Taylor & Francis Journals, vol. 48(27), pages 2562-2570, June.
    14. Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Manuel Posada-de-la-Paz & Pedro Serrano-Aguilar & Panos Kanavos & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & Petra Baji & Clau, 2016. "Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 99-108, April.
    15. Todd Gammie & Christine Y Lu & Zaheer Ud-Din Babar, 2015. "Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-24, October.
    16. Julio López-Bastida & Juan Oliva-Moreno & Renata Linertová & Pedro Serrano-Aguilar, 2016. "Social/economic costs and health-related quality of life in patients with rare diseases in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 1-5, April.
    17. Karine Chevreul & Morgane Michel & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schiep, 2016. "Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 7-18, April.
    18. Lokman I. Meho & Kiduk Yang, 2007. "Impact of data sources on citation counts and rankings of LIS faculty: Web of science versus scopus and google scholar," Journal of the American Society for Information Science and Technology, Association for Information Science & Technology, vol. 58(13), pages 2105-2125, November.
    19. Helen Crompton, 2007. "Mode 2 knowledge production: Evidence from orphan drug networks," Science and Public Policy, Oxford University Press, vol. 34(3), pages 199-211, April.
    20. Robinson, Suzanne & Williams, Iestyn & Dickinson, Helen & Freeman, Tim & Rumbold, Benedict, 2012. "Priority-setting and rationing in healthcare: Evidence from the English experience," Social Science & Medicine, Elsevier, vol. 75(12), pages 2386-2393.
    21. Marialuisa Saviano & Clara Bassano & Paolo Piciocchi & Primiano Di Nauta & Mattia Lettieri, 2018. "Monitoring Viability and Sustainability in Healthcare Organizations," Sustainability, MDPI, vol. 10(10), pages 1-23, October.
    22. Douglas, Conor M.W. & Wilcox, Elizabeth & Burgess, Michael & Lynd, Larry D., 2015. "Why orphan drug coverage reimbursement decision-making needs patient and public involvement," Health Policy, Elsevier, vol. 119(5), pages 588-596.
    23. Sergio Barile & Marialuisa Saviano & Francesca Iandolo & Mario Calabrese, 2014. "The Viable Systems Approach and its Contribution to the Analysis of Sustainable Business Behaviors," Systems Research and Behavioral Science, Wiley Blackwell, vol. 31(6), pages 683-695, November.
    24. Thomas Hemphill, 2010. "Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?," Journal of Business Ethics, Springer, vol. 94(2), pages 225-242, June.
    25. Mike Paulden & Tania Stafinski & Devidas Menon & Christopher McCabe, 2015. "Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework," PharmacoEconomics, Springer, vol. 33(3), pages 255-269, March.
    26. Padhraig S Fleming & Despina Koletsi & Nikolaos Pandis, 2014. "Blinded by PRISMA: Are Systematic Reviewers Focusing on PRISMA and Ignoring Other Guidelines?," PLOS ONE, Public Library of Science, vol. 9(5), pages 1-7, May.
    27. A. Kuhlmann & T. Schmidt & M. Treskova & J. López-Bastida & R. Linertová & J. Oliva-Moreno & P. Serrano-Aguilar & M. Posada-de-la-Paz & P. Kanavos & D. Taruscio & A. Schieppati & G. Iskrov & M. Péntek, 2016. "Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 79-87, April.
    28. Tom Kuhlman & John Farrington, 2010. "What is Sustainability?," Sustainability, MDPI, vol. 2(11), pages 1-13, November.
    29. Boon, Wouter & Moors, Ellen, 2008. "Exploring emerging technologies using metaphors - A study of orphan drugs and pharmacogenomics," Social Science & Medicine, Elsevier, vol. 66(9), pages 1915-1927, May.
    30. Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Panos Kanavos & Domenica Taruscio & Arrigo Schieppati & Georgi Iskrov & Márta Péntek & Cl, 2016. "Social/economic costs and health-related quality of life in patients with scleroderma in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 109-117, April.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ajay Chandra & S. D. Sreeganga & Nibedita Rath & Arkalgud Ramaprasad, 2023. "Healthcare Policies to Eliminate Neglected Tropical Diseases (NTDs) in India: A Roadmap," IJERPH, MDPI, vol. 20(19), pages 1-19, September.
    2. Francesco Caputo & Pierpaolo Magliocca & Rossella Canestrino & Erika Rescigno, 2023. "Rethinking the Role of Technology for Citizens’ Engagement and Sustainable Development in Smart Cities," Sustainability, MDPI, vol. 15(13), pages 1-19, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. López-Bastida, J. & Ramos-Goñi, J.M. & Aranda-Reneo, I. & Trapero-Bertran, M. & Kanavos, P. & Rodriguez Martin, B., 2019. "Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?," Health Policy, Elsevier, vol. 123(2), pages 152-158.
    2. Luz María Peña-Longobardo & Isaac Aranda-Reneo & Juan Oliva-Moreno & Svenja Litzkendorf & Isabelle Durand-Zaleski & Eduardo Tizzano & Julio López-Bastida, 2020. "The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe," IJERPH, MDPI, vol. 17(16), pages 1-12, August.
    3. Isaac Aranda-Reneo & Luz María Peña-Longobardo & Juan Oliva-Moreno & Svenja Litzkendorf & Isabelle Durand-Zaleski & Eduardo F. Tizzano & Julio López-Bastida, 2020. "The Burden of Spinal Muscular Atrophy on Informal Caregivers," IJERPH, MDPI, vol. 17(23), pages 1-12, December.
    4. Alicia Aurora Rodríguez & Óscar Martínez & Imanol Amayra & Juan Francisco López-Paz & Mohammad Al-Rashaida & Esther Lázaro & Patricia Caballero & Manuel Pérez & Sarah Berrocoso & Maitane García & Paul, 2021. "Diseases Costs and Impact of the Caring Role on Informal Carers of Children with Neuromuscular Disease," IJERPH, MDPI, vol. 18(6), pages 1-16, March.
    5. Alicia Aurora Rodríguez & Imanol Amayra & Juan Francisco López-Paz & Oscar Martínez & Maitane García & Mónika Salgueiro & Mohammad Al-Rashaida & Paula María Luna & Paula Pérez-Nuñez & Nicole Passi & I, 2022. "The Role of Associations in Reducing the Emotional and Financial Impact on Parents Caring for Children with Duchenne Muscular Dystrophy: A Cross-Cultural Study," IJERPH, MDPI, vol. 19(19), pages 1-15, September.
    6. Valentin Brodszky & Zsuzsanna Beretzky & Petra Baji & Fanni Rencz & Márta Péntek & Alexandru Rotar & Konstantin Tachkov & Susanne Mayer & Judit Simon & Maciej Niewada & Rok Hren & László Gulácsi, 2019. "Cost-of-illness studies in nine Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 155-172, June.
    7. Alvaro Rafael Villar Hernández & Fernando Molero Alonso & Álvaro Jesús Aguado Marín & Manuel Posada de la Paz, 2022. "Transcultural Validation of a Spanish Version of the Quality of Life in Epidermolysis Bullosa Questionnaire," IJERPH, MDPI, vol. 19(12), pages 1-11, June.
    8. Michela Meregaglia & Elena Nicod & Michael Drummond, 2023. "The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1151-1216, September.
    9. Yllka Kodra & Marianna Cavazza & Marta de Santis & Andrea Guala & Maria-Elena Liverani & Patrizio Armeni & Maura Masini & Domenica Taruscio, 2020. "Social Economic Costs, Health-Related Quality of Life and Disability in Patients with Cri Du Chat Syndrome," IJERPH, MDPI, vol. 17(16), pages 1-14, August.
    10. Takeya Adachi & Ayman W. El-Hattab & Ritu Jain & Katya A. Nogales Crespo & Camila I. Quirland Lazo & Maurizio Scarpa & Marshall Summar & Duangrurdee Wattanasirichaigoon, 2023. "Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges," IJERPH, MDPI, vol. 20(6), pages 1-37, March.
    11. Javier Güeita-Rodriguez & Pilar Famoso-Pérez & Jaime Salom-Moreno & Pilar Carrasco-Garrido & Jorge Pérez-Corrales & Domingo Palacios-Ceña, 2020. "Challenges Affecting Access to Health and Social Care Resources and Time Management among Parents of Children with Rett Syndrome: A Qualitative Case Study," IJERPH, MDPI, vol. 17(12), pages 1-16, June.
    12. Patrizio Armeni & Marianna Cavazza & Entela Xoxi & Domenica Taruscio & Yllka Kodra, 2021. "Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal," IJERPH, MDPI, vol. 18(3), pages 1-18, January.
    13. Petra Baji & Dominik Golicki & Valentina Prevolnik-Rupel & Werner B. F. Brouwer & Zsombor Zrubka & László Gulácsi & Márta Péntek, 2019. "The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 5-16, June.
    14. Belousova, Olga A. & Groen, Aard J. & Ouendag, Aniek M., 2020. "Opportunities and barriers for innovation and entrepreneurship in orphan drug development," Technological Forecasting and Social Change, Elsevier, vol. 161(C).
    15. Francesco Polese & Luca Carrubbo & Francesco Caputo & Debora Sarno, 2018. "Managing Healthcare Service Ecosystems: Abstracting a Sustainability-Based View from Hospitalization at Home (HaH) Practices," Sustainability, MDPI, vol. 10(11), pages 1-15, October.
    16. Nicod, Elena & Annemans, Lieven & Bucsics, Anna & Lee, Anne & Upadhyaya, Sheela & Facey, Karen, 2019. "HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries," Health Policy, Elsevier, vol. 123(2), pages 140-151.
    17. Francesco Polese & Carmen Gallucci & Luca Carrubbo & Rosalia Santulli, 2021. "Predictive Maintenance as a Driver for Corporate Sustainability: Evidence from a Public-Private Co-Financed R&D Project," Sustainability, MDPI, vol. 13(11), pages 1-21, May.
    18. Evert Gummesson & Debora Sarno & Luca Carrubbo & Carlo Sirianni, 2021. "Contributing to Sustainable Healthcare Systems with Case Theory," International Journal of Business and Management, Canadian Center of Science and Education, vol. 14(2), pages 1-34, July.
    19. Jason C Hsu & Huai-Chueh Wu & Wen-Chia Feng & Chih-Ho Chou & Edward Chia-Cheng Lai & Christine Y Lu, 2018. "Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan’s National Health Insurance Research Database," PLOS ONE, Public Library of Science, vol. 13(9), pages 1-14, September.
    20. Vincenzo Basile & Francesca Loia & Nunzia Capobianco & Roberto Vona, 2023. "An ecosystems perspective on the reconversion of offshore platforms: Towards a multi‐level governance," Corporate Social Responsibility and Environmental Management, John Wiley & Sons, vol. 30(4), pages 1615-1631, July.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jsusta:v:11:y:2019:i:5:p:1289-:d:210054. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.